×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CPRX – catalyst pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CPRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/9
07:03 pm
cprx
Does Forbes' Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)? [Yahoo! Finance]
Low
Report
Does Forbes' Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)? [Yahoo! Finance]
1/9
04:31 am
cprx
Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause? [Yahoo! Finance]
Low
Report
Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause? [Yahoo! Finance]
1/8
08:03 am
cprx
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
Low
Report
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
1/5
08:40 am
cprx
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) [Yahoo! Finance]
Low
Report
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) [Yahoo! Finance]
1/5
08:03 am
cprx
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
Low
Report
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
12/31
11:40 am
cprx
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? [Yahoo! Finance]
12/24
04:13 pm
cprx
Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "buy (b-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "buy (b-)" rating reaffirmed by analysts at Weiss Ratings.
12/18
04:34 pm
cprx
Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "buy (b-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "buy (b-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
04:06 pm
cprx
catalyst pharmaceuticals, inc.
BEAT
Report
-6.8%
catalyst pharmaceuticals, inc.
8/6/2025
04:13 pm
cprx
catalyst pharmaceuticals, inc.
BEAT
Report
-9.8%
catalyst pharmaceuticals, inc.
5/7/2025
04:14 pm
cprx
catalyst pharmaceuticals, inc.
BEAT
Report
-6.2%
catalyst pharmaceuticals, inc.
2/26/2025
04:13 pm
cprx
catalyst pharmaceuticals, inc.
BEAT
Report
-0.7%
catalyst pharmaceuticals, inc.
Date
Time
Symbol
Headline
Impact
1/12
08:03 am
cprx
Form 8-K CATALYST PHARMACEUTICALS For: Jan 12
Low
Report
Form 8-K CATALYST PHARMACEUTICALS For: Jan 12
1/6
05:01 pm
cprx
Form 4 CATALYST PHARMACEUTICALS For: Jan 05 Filed by: Kalb Michael Wayne
Low
Report
Form 4 CATALYST PHARMACEUTICALS For: Jan 05 Filed by: Kalb Michael Wayne
1/6
05:00 pm
cprx
Form 4 CATALYST PHARMACEUTICALS For: Jan 05 Filed by: Daly Richard J
Low
Report
Form 4 CATALYST PHARMACEUTICALS For: Jan 05 Filed by: Daly Richard J
12/30
05:01 pm
cprx
Form 4 CATALYST PHARMACEUTICALS For: Dec 29 Filed by: DENKHAUS DONALD A
Low
Report
Form 4 CATALYST PHARMACEUTICALS For: Dec 29 Filed by: DENKHAUS DONALD A
12/30
05:00 pm
cprx
Form 4 CATALYST PHARMACEUTICALS For: Dec 29 Filed by: Elsbernd Brian
Low
Report
Form 4 CATALYST PHARMACEUTICALS For: Dec 29 Filed by: Elsbernd Brian
12/30
05:00 pm
cprx
Form 4 CATALYST PHARMACEUTICALS For: Dec 29 Filed by: Tierney David S
Low
Report
Form 4 CATALYST PHARMACEUTICALS For: Dec 29 Filed by: Tierney David S
12/30
05:00 pm
cprx
Form 4 CATALYST PHARMACEUTICALS For: Dec 29 Filed by: Daly Richard J
Low
Report
Form 4 CATALYST PHARMACEUTICALS For: Dec 29 Filed by: Daly Richard J
12/30
05:00 pm
cprx
Form 4 CATALYST PHARMACEUTICALS For: Dec 29 Filed by: MCENANY PATRICK J
Low
Report
Form 4 CATALYST PHARMACEUTICALS For: Dec 29 Filed by: MCENANY PATRICK J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/9
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.
15.9%
5/14 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was given a new $9.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 12.7%
4/8 Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities 11.5%
1/6 Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs 11.1%
3/10 Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020 9.8%
2/5 Form 8-K CATALYST PHARMACEUTICALS For: Feb 04 9.5%
3/16 Q4/2019 12/31/2019 EPS 0.070 ZacksConsensus 0.090 ActVsEst (0.020) - Miss 8.6%
6/12 Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration 7.9%
11/13 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) had its price target lowered by analysts at Piper Jaffray Companies from $8.00 to $7.00. 5.6%
9/24 Form 8-K CATALYST PHARMACEUTICALS For: Sep 23 5.5%
5/14 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was given a new $9.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 12.7%
4/8 Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities 11.5%
1/6 Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs 11.1%
3/10 Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020 9.8%
2/5 Form 8-K CATALYST PHARMACEUTICALS For: Feb 04 9.5%
3/16 Q4/2019 12/31/2019 EPS 0.070 ZacksConsensus 0.090 ActVsEst (0.020) - Miss 8.6%
6/12 Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration 7.9%
11/13 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) had its price target lowered by analysts at Piper Jaffray Companies from $8.00 to $7.00. 5.6%
9/24 Form 8-K CATALYST PHARMACEUTICALS For: Sep 23 5.5%
TOP News Decliners
3/15
Catalyst Pharmaceuticals Q4 2019 Earnings Preview [Seeking Alpha]
-23.2%
9/11 Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock -14.9%
10/30 Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS) -14.5%
4/14 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -12.1%
5/13 Form 8-K CATALYST PHARMACEUTICALS For: May 13 -11.7%
8/7 Q2/2019 6/30/2019 EPS 0.100 ZacksConsensus 0.030 ActVsEst 0.070 - Beat -10.7%
2/27 Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020 -10.3%
12/20 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -8.9%
9/13 Form 8-K CATALYST PHARMACEUTICALS For: Sep 13 -8.0%
11/12 Form 10-Q CATALYST PHARMACEUTICALS For: Sep 30 -7.3%
9/11 Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock -14.9%
10/30 Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS) -14.5%
4/14 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -12.1%
5/13 Form 8-K CATALYST PHARMACEUTICALS For: May 13 -11.7%
8/7 Q2/2019 6/30/2019 EPS 0.100 ZacksConsensus 0.030 ActVsEst 0.070 - Beat -10.7%
2/27 Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020 -10.3%
12/20 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -8.9%
9/13 Form 8-K CATALYST PHARMACEUTICALS For: Sep 13 -8.0%
11/12 Form 10-Q CATALYST PHARMACEUTICALS For: Sep 30 -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: